



Variations in Risk of End-Stage Renal Disease and Risk of Mortality in an International Study of Patients With Type 1 Diabetes and Advanced Nephropathy

Diabetes Care 2019;42:93–101 | <https://doi.org/10.2337/dc18-1369>

Jan Skupien,^{1,2} Adam M. Smiles,²
Erkka Valo,³ Tarunveer S. Ahluwalia,⁴
Beata Gyorgy,⁵ Niina Sandholm,³
Stephanie Croall,² Maria Lajer,⁴
Kevin McDonnell,² Carol Forsblom,³
Valma Harjutsalo,^{3,6} Michel Marre,⁷
Andrzej T. Galecki,^{8,9}
David-Alexandre Tregouet,⁵ Chun Yi Wu,⁸
Josyf C. Mychaleckyj,¹⁰ Helen Nickerson,¹¹
Marlon Pragnell,¹¹ Stephen S. Rich,¹⁰
Marcus G. Pezolesi,¹² Samy Hadjadj,^{13,14}
Peter Rossing,^{4,15} Per-Henrik Groop,^{3,16} and
Andrzej S. Krolewski^{2,17}

OBJECTIVE

Patients with type 1 diabetes and diabetic nephropathy are targets for intervention to reduce high risk of end-stage renal disease (ESRD) and deaths. This study compares risks of these outcomes in four international cohorts.

RESEARCH DESIGN AND METHODS

In the 1990s and early 2000s, Caucasian patients with type 1 diabetes with persistent macroalbuminuria in chronic kidney disease stages 1–3 were identified in the Joslin Clinic (U.S., 432), Finnish Diabetic Nephropathy Study (FinnDiane) (Finland, 486), Steno Diabetes Center Copenhagen (Denmark, 368), and INSERM (France, 232) and were followed for 3–18 years with annual creatinine measurements to ascertain ESRD and deaths unrelated to ESRD.

RESULTS

During 15,685 patient-years, 505 ESRD cases (rate 32/1,000 patient-years) and 228 deaths unrelated to ESRD (rate 14/1,000 patient-years) occurred. Risk of ESRD was associated with male sex; younger age; lower estimated glomerular filtration rate (eGFR); higher albumin/creatinine ratio, HbA_{1c}, and systolic blood pressure; and smoking. Risk of death unrelated to ESRD was associated with older age, smoking, and higher baseline eGFR. In adjusted analysis, ESRD risk was highest in Joslin versus reference FinnDiane (hazard ratio [HR] 1.44, $P = 0.003$) and lowest in Steno (HR 0.54, $P < 0.001$). Differences in eGFR slopes paralleled risk of ESRD. Mortality unrelated to ESRD was lowest in Joslin (HR 0.68, $P = 0.003$ vs. the other cohorts). Competing risk did not explain international differences in the outcomes.

CONCLUSIONS

Despite almost universal renoprotective treatment, progression to ESRD and mortality in patients with type 1 diabetes with advanced nephropathy are still very high and differ among countries. Finding causes of these differences may help reduce risk of these outcomes.

Patients with type 1 diabetes with advanced diabetic nephropathy defined as macroalbuminuria are at high risk of end-stage renal disease (ESRD) and death (1–4). These patients are targets for aggressive interventions with both existing and new renoprotective therapies. Studies on the natural history of advanced diabetic

¹Department of Metabolic Diseases, Jagiellonian University Medical College, Krakow, Poland

²Research Division, Joslin Diabetes Center, Boston, MA

³Folkhälsan Institute of Genetics, Folkhälsan Research Center; Abdominal Center, Nephrology, University of Helsinki and Helsinki University Hospital; and Research Programs Unit, Diabetes and Obesity, University of Helsinki, Helsinki, Finland

⁴Steno Diabetes Center Copenhagen, Copenhagen, Denmark

⁵Sorbonne Université, Université Pierre-et-Marie-Curie (UPMC) Paris 06 INSERM UMR S 1166, and Department of Genomics and Pathophysiology of Cardiovascular Diseases, Institute of Cardiometabolism and Nutrition, Paris, France

⁶Chronic Disease Prevention Unit, National Institute for Health and Welfare, Helsinki, Finland

⁷Diabetes Department, Hôpital Bichat-Claude Bernard, Assistance Publique des Hôpitaux de Paris, Université Denis Diderot Paris 7 and INSERM U1138, Paris, France

⁸Institute of Gerontology, University of Michigan Medical School, Ann Arbor, MI

⁹Department of Biostatistics, University of Michigan School of Public Health, Ann Arbor, MI

¹⁰Center for Public Health Genomics, University of Virginia, Charlottesville, VA

¹¹JDRF International, New York, NY

¹²Division of Nephrology and Hypertension, University of Utah, Salt Lake City, UT

¹³INSERM CIC 1402 and U 1082, and Department of Endocrinology and Diabetology, CHU Poitiers, Poitiers, France

¹⁴Department of Endocrinology, L'institut du thorax, CIC 1413 INSERM, CHU Nantes, Nantes, France

nephropathy are limited. Some of these studies provide descriptive data about historical cohorts not subjected to current interventions and frequently consider only ESRD or total mortality, not distinguishing risk of ESRD from risk of deaths unrelated to ESRD (1–4). In more recent studies, lack of standardization regarding study design, risk factors, and definition of outcomes did not allow for comparisons among centers and countries (5–7).

Recent publications described an experience of specific inception cohorts (registries) of patients with type 1 diabetes and showed significant differences among countries (8–12). Those studies were nicely reviewed in a recent editorial (13). However, the studies did not allow the determination of probable causes of such differences. For example, could the differences be due to better primary prevention, mainly good glyce-mic control before patients developed diabetic nephropathy, secondary inter-ventions in patients with diabetic nephropathy, differences in study de-signs, or distributions of risk factors? Or, finally, if all factors are considered and the differences persist, are they due to genetic or environmental factors?

The opportunity to answer the above questions with regard to patients with type 1 diabetes with advanced diabetic nephropathy subjected to the contem-porary therapeutic protocols was pro-vided by the recent JDRF Diabetic Nephropathy Collaborative Research Ini-tiative (DNCRI). This study dissects the genetic architecture of diabetic nephrop-athy in type 1 diabetes. The subproject entitled “Genes determining time of onset of ESRD in type 1 diabetes” con-tributes to the DNCRI through studies of the genetics of time to ESRD and of rate of estimated glomerular filtration rate (eGFR) loss as a quantitative phenotype, rather than by the traditional case-control study design. For the subproject, participants were assembled from 3–18 years of follow-up studies of cohorts of patients with type 1 diabetes and

proteinuria from Finland (Finnish Dia-betic Nephropathy Study [FinnDiane]), U.S. (Joslin Diabetes Center), Denmark (Steno Diabetes Center Copenhagen), and France/Belgium (Institut National de la Santé et de la Recherche Médicale [INSERM]). In this report, we compare the natural history of advanced diabetic nephropathy in type 1 diabetes among these four cohorts by comparing distri-butions of eGFR slopes and risk of ESRD and mortality unrelated to ESRD, con-trolling for different distributions of risk factors.

RESEARCH DESIGN AND METHODS

The study protocols and informed con-sent procedures for recruitment, exam-ination, and follow-up of the study participants were concordant with the Declaration of Helsinki and were ap-proved by the relevant institutional re-view boards or bioethics committees.

Patients and Eligibility Criteria

All cohorts were ascertained for the purpose of follow-up studies to investi-gate the natural history of diabetic nephropathy in type 1 diabetes, including characterizing standard and novel bio-markers and the role of genetic factors of renal decline (5–7,14–21). Enrollment and baseline examinations took place through the 1990s and early 2000s, with follow-up through 2013. We included individuals with baseline eGFR ≥ 30 mL/min/1.73 m² who were alive within 1 year of follow-up and had at least a 42-month follow-up if free from ESRD.

Joslin Proteinuria Cohort

A total of 3,500 adult individuals with type 1 diabetes remain under the care of Joslin Clinic, an institution established in 1898 and devoted to treatment of di-abetes (6). The majority come to the clinic within the first 5 years of diabetes di-agnosis, and they remain under care for a long period of time, frequently for life (14,15). Between 1991 and 2004, we monitored the occurrence of persistent

macroalbuminuria, and patients with es-tablished type 1 diabetes diagnosis in medical records, residence in New Eng-land, and age at enrollment between 21 and 54 years were approached by trained recruiters. Between 1991 and 2004, out of 784 patients, 432 consented for participation and met eligibility cri-teria for the current study. Enrolled participants were followed until 2013, with the goal of obtaining blood and urine specimens at least every 2 years. Collection of research specimens oc-curred during routine clinic visits. Pa-tients with less frequent clinic visits or those who stopped coming to the clinic were examined at their homes.

FinnDiane Proteinuria Cohort

FinnDiane was initiated in 1997 with the aim of studying clinical, biochemical, environmental, and genetic risk factors for diabetes complications in patients with type 1 diabetes (16). Prior to that, a pilot study was conducted be-tween 1994 and 1997. The FinnDiane is a nationwide prospective multicenter study including 93 centers in Finland. All university hospitals ($n = 5$), all central hospitals ($n = 16$), all district hospitals that treat patients with type 1 diabetes ($n = 28$), and the largest health care centers ($n = 44$) are involved. Adult patients (aged >18 years) with type 1 diabetes defined based on age at onset of diabetes <40 years and insulin treat-ment initiated within 1 year of diagnosis were asked to participate in the study. Although the study is not by definition a population-based study, the patient dis-tribution follows that of the general Finnish population.

So far, more than 5,000 patients have participated in the FinnDiane study. Pa-tients were initially studied between 1994 and 2013 and were thereafter followed either by prospective FinnDiane visits at the local centers or by following them through medical files and registries. Follow-up data, including serial measure-ments of serum creatinine, were avail-able for 630 out of 898 patients with

¹⁵University of Copenhagen, Copenhagen, Denmark

¹⁶Department of Diabetes, Central Clinical School, Monash University, Melbourne, Victoria, Australia

¹⁷Department of Medicine, Harvard Medical School, Boston, MA

Corresponding authors: Jan Skupien, jan.skupien@uj.edu.pl, and Andrzej S. Krolewski, andrzej.krolewski@joslin.harvard.edu

Received 26 June 2018 and accepted 27 Septem-ber 2018

© 2018 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More infor-mation is available at <http://www.diabetesjournals.org/content/license>.

macroalbuminuria (7,17), and 486 met further eligibility criteria.

Steno Proteinuria Cohort

Steno Diabetes Center Copenhagen is a tertiary highly specialized diabetes center in the Capital Region of Denmark. The patients included in the cohort are participants in the previously described study of patients with type 1 diabetes and diabetic nephropathy and a matched control group with long duration of diabetes (18). This cohort was supplemented with patients included up to 2009 according to the same protocol.

From 1993 to 2009, adult Caucasian (self-declared) patients with type 1 diabetes and diabetic nephropathy attending the outpatient clinic at Steno Diabetes Center Copenhagen were invited to participate in a study of genetic risk factors for the development of diabetes complications. Type 1 diabetes was considered present if age at onset of diabetes was <35 years and time to definite insulin therapy was <1 year. In total, 540 patients with persistent macroalbuminuria, the presence of diabetic retinopathy, and the absence of other kidney or urinary tract disease were enrolled. Eligibility criteria of the current study were met by 368 patients.

INSERM Proteinuria Cohort

The cohort details were recently published (21). Briefly, individuals of European ethnicity (based on genetic identification) were recruited on the occasion of the GENEDIAB (Genétique de la Néphropathie Diabétique) and GENESIS (Genetics Nephropathy and Sib Pair Study) studies (19,20). In addition, consecutive nonduplicate patients in enrollment centers

in Corbeil-Essonnes, Nantes, Paris Saint-Louis, Poitiers, and Toulouse were recruited (21). Inclusion criteria for the GENEDIAB study included severe diabetic retinopathy (proliferative or severe nonproliferative requiring panphotocoagulation), while patients with retinopathy and diabetes duration >15 years were eligible for the GENESIS study. Type 1 diabetes was defined as the age of onset <35 years (GENESIS and GENEDIAB) or <40 years (other centers) and a definitive requirement for insulin treatment <1 year following diagnosis. Ascertainment of study participants was all hospital based. There were 232 patients meeting eligibility criteria for the current study.

The comparison of the ascertainment of the four cohorts is shown in Table 1. In total, 2,678 patients with macroalbuminuria and an additional 523 with prevalent ESRD had available DNA samples and were initially recruited in the JDRF DNCRI project. For the current study, 1,518 Caucasian participants from the four cohorts met the inclusion criteria.

Assessment of Abnormalities in Urinary Albumin Excretion

In the Joslin Clinic laboratory, albumin concentrations were measured with immunonephelometry in spot urines at least once a year. Creatinine measurements in urine were assayed by the Jaffe modified picrate method to calculate albumin/creatinine ratio. (The persistent macroalbuminuria status was established if at least two out of three measurements collected during a 2-year interval preceding study enrollment were >300 mg/g (6). In FinnDiane, macroalbuminuria was defined as urinary

albumin excretion rate (AER) ≥ 200 $\mu\text{g}/\text{min}$ or ≥ 300 mg/24 h or an ACR ≥ 25 mg/mmol in men and ACR ≥ 35 mg/mmol in women in at least two out of three overnight, 24-h urine collections (AER) or first morning void urine samples (ACR). Persistent macroalbuminuria was established if at least two out of three consecutive urine collections were within the macroalbuminuria range (7). In Steno Diabetes Center Copenhagen, urinary AER was measured at least once per year by an enzyme immunoassay in 24-h urine collections. In addition, urinary ACRs were also available. AER >300 mg/24 h in at least two out of three consecutive measurements was considered persistent macroalbuminuria. Arbitrarily, the date for fulfilling the persistent macroalbuminuria criterion was set as the date of the second sample within the range of macroalbuminuria. In the GENESIS and GENEDIAB cohorts, baseline urinary albumin concentration was centrally determined using immunonephelometry, while the patients recruited through five hospital centers had their AER determined locally. To determine persistent macroalbuminuria, at least two out of three consecutive AER measurements in sterile urine collections had to fall in the range of macroalbuminuria (>300 mg/24 h). ACR was not available in all study patients.

Assessment of Renal Function

In Joslin Clinic, Steno Diabetes Center Copenhagen (until 2004), and FinnDiane (at the central laboratory of the Helsinki University Central Hospital until January 2002), serum creatinine was measured with the Jaffe modified picrate method

Table 1—Patients enrolled in the four type 1 diabetes cohorts with macroalbuminuria or prevalent ESRD and numbers of eligible patients in the current study

	Participating center				Total
	Joslin	FinnDiane	Steno	INSERM	
Years of recruitment*	1993–2002	1998–2001	1993–1999	1993–1998	
Number of patients recruited	784	898	540	456	2,678
Number of eligible patients in CKD stages 1–3¶	432 (199)†	486 (253)†	368 (182)†	232 (99)†	1,518 (733)†
Number of patients in CKD stages 4–5	69 (68)†	66 (63)†	32 (31)†	71 (61)†	238 (223)†
Number of noneligible patients	283	346	140	153	922
Number of patients with prevalent ESRD	220	268	35	0	523

*Years of recruitment indicate calendar years during which 25th and 75th percentiles of the patients were enrolled into the follow-up study.

¶Patients were eligible for the study if they 1) had type 1 diabetes, had persistent macroalbuminuria at baseline, and had at least a 42-month follow-up time with eGFR determinations; 2) had type 1 diabetes, had persistent macroalbuminuria at baseline, and developed ESRD during follow-up; 3) had type 1 diabetes, had persistent macroalbuminuria at baseline, and had at least a 12-month follow-up time before death unrelated to ESRD.

†Data in parentheses show the number of patients who progressed to ESRD or died due to causes unrelated to ESRD during follow-up.

and with an enzymatic method thereafter. In the FinnDiane study, most serum creatinine determinations came from local hospital laboratories. In 2010 in FinnDiane and in 2011–2014 in Joslin, a subset of serum specimens were reassayed in the Advanced Research and Diagnostic Laboratory at the University of Minnesota using the Roche enzymatic assay (product no. 11775685) on a Roche/Hitachi Mod P analyzer. This method has been calibrated to be traceable to an isotope dilution mass spectrometry (IDMS) reference assay and was verified by measuring National Institute of Standards and Technology Standard Reference Material (NIST SRM) no. 967. These duplicate measurements were used to calibrate the clinical measurements (22). In Steno, the measurements performed with the Jaffe method were transformed to an IDMS traceable standard, as described previously (23). Baseline samples from patients in the GENEDIAB and GENESIS cohorts were assayed centrally for serum creatinine, while the measurements were performed locally in the five recruiting centers. During follow-up, serum creatinine was measured using colorimetric methods with different appliances according to the local practice. In all cohorts, the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula was used to estimate eGFR (24). Only serum creatinine determinations prior to ESRD diagnosis were taken into account in the analysis of eGFR trajectories.

Ascertainment of Onset of ESRD and Mortality Unrelated to ESRD

All patients from the Joslin cohort were queried against rosters of the United States Renal Data System and the National Death Index covering all events up to the end of 2013. In the FinnDiane cohort, data regarding onset of ESRD were obtained from the Care Register for Health Care (HILMO) in Finland and were then verified using patients' medical files. No patients in the FinnDiane study received a preemptive kidney transplantation without prior dialysis. Data on mortality and causes of death were retrieved from Statistics Finland and were confirmed using death certificates. Both queries covered all events up to the end of 2013 (17). In Steno Diabetes Center Copenhagen, information about ESRD was

obtained from patient records or discharge letters from other hospitals. The Danish Register of Causes of Death provided information on deaths. In the INSERM cohort, hospital records were analyzed for identification of the presence and date of onset of ESRD or death, and, in cases of missing data, general practitioners were interviewed by telephone. The national death certificate registry was consulted when no data were available.

The onset of ESRD was given as the date of first dialysis or transplantation or the date of death for those captured by death certificate. In all cohorts, if ESRD did not develop and death was ascertained, the outcome was defined as "death unrelated to ESRD."

Clinical Characteristics at Baseline Examination

All patients enrolled into the study had a standardized examination performed at baseline. This examination included an interview regarding past history of type 1 diabetes, its complications and history of treatment (specifically with renoprotective and antihypertensive drugs), and presence of standard risk factors, such as smoking history. In addition, patients had standardized measurements of blood pressure, height, and weight and measurements of HbA_{1c} (performed locally with high-performance liquid chromatography and Diabetes Control and Complications Trial-adjusted) and serum lipids (lipids were not available for all INSERM patients).

Statistical Analysis

Continuous variables were summarized as medians and quartiles while categorical variables were presented as counts, proportions, and percentages. Incidence rates of ESRD and mortality rates due to deaths unrelated to ESRD were used to describe the follow-up results in each cohort. The cumulative incidence function of ESRD and cumulative incidence of mortality unrelated to ESRD were determined accounting for competing risks. To adjust for baseline differences in covariates within the framework of competing risks, multivariate Fine and Gray proportional subhazards survival regression models were used, with ESRD and deaths unrelated to ESRD as competing events (25). Deviations from proportionality of hazards were

tested with interaction terms of tertiles of follow-up time (not statistically significant, $P > 0.05$). To account for informative censoring of follow-up time in patients with rapid eGFR loss, a joint longitudinal-survival model was used to describe renal function decline (26,27). Both the eGFR time-series data and times to ESRD or censoring were used to obtain estimates of mean rates of renal (eGFR) decline in the cohorts, an approach that is robust with regard to heterogeneity of baseline renal function (eGFR) at enrollment and variable duration of follow-up (27). Statistical significance was set at a $P < 0.05$. Analyses were performed in SAS for Windows, version 9.3 (SAS Institute, Cary, NC) and R software version 3.3.1 with 'cmprsk' package (The R Foundation for Statistical Computing, Vienna, Austria).

RESULTS

Characteristics of the Study Cohorts

There were 1,518 eligible patients with type 1 diabetes with persistent macroalbuminuria and in chronic kidney disease (CKD) stages 1–3 enrolled from Joslin, FinnDiane, Steno, and INSERM to the follow-up study on natural history of advanced diabetic nephropathy. Baseline characteristics of these patients according to study cohort are presented in Table 2. Patients for two cohorts, Joslin and Steno, were ascertained at single specialty clinics with a long tradition of providing long-term care for patients with diabetes. In contrast, FinnDiane enrolled patients who remained under care of multiple local clinics nationwide. A large number of subjects in INSERM were patients initially enrolled in the GENEDIAB and GENESIS projects in 38 diabetes or nephrology clinics in France and Belgium.

The cohorts did not differ with respect to male and female proportions and serum cholesterol level. There were statistically significant but clinically small differences in age at enrollment and age at diagnosis of type 1 diabetes. Joslin cohort subjects had shorter diabetes duration before study enrollment, higher baseline eGFR, and lower systolic blood pressure. Blood pressure control was good (median systolic 130–140 mmHg) across the cohorts, while glycemic control was largely inadequate (median HbA_{1c} ranging from 8.7% or 72 mmol/mol in the INSERM to 9.2% or 77 mmol/mol in the Steno cohort).

Table 2—Baseline characteristics of the four study cohorts of patients with type 1 diabetes with persistent macroalbuminuria in CKD stages 1–3 at baseline

Characteristic	Joslin cohort (n = 432)	FinnDiane cohort (n = 486)	Steno cohort (n = 368)	INSERM cohort (n = 232)	P value
Men (%)	57.2	60.3	61.1	59.9	0.68
Age (years)	37 (32, 43)	39 (32, 48)	40 (33, 48)	41 (32, 50)	<0.001
Age at diabetes diagnosis (years)	12 (8, 20)	10 (7, 15)	10 (7, 15)	13.5 (8.5, 21)	<0.001
Duration of diabetes (years)	23 (17, 30)	27 (22, 31)	27 (22, 32.5)	26 (18.5, 33)	<0.001
Urinary ACR (mg/g)	718 (420, 1,337)	321 (122, 786)	581 (273, 1,489)		<0.001*
Urinary albumin (mg/L)				497 (181, 1,110)	
eGFR (mL/min/1.73 m ²)	88 (69, 109)	70 (49, 93)	75 (58, 96)	74 (56, 94)	<0.001
Systolic blood pressure (mmHg)	131 (120, 142)	141 (130, 155)	140.5 (127.5, 154.5)	140 (130, 155)	<0.001
Antihypertensive treatment (%)	74.8	94.8	81.5	82.3	<0.001
HbA _{1c}					
%	9.0 (7.9, 10.2)	8.8 (8.0, 10.0)	9.2 (8.2, 10.1)	8.7 (7.7, 9.8)	
mmol/mol	75 (63, 88)	73 (64, 86)	77 (66, 87)	72 (61, 84)	0.002
Total cholesterol (mmol/L)	5.3 (4.5, 6.1)	5.3 (4.7, 6.0)	5.5 (4.7, 6.2)		0.19*
Smoking status					
Never (%)	46.1	38.4		47.4	
Former (%)	29.9	29.0		16.4	<0.001*
Current (%)	24.0	32.6	44.0	36.2	<0.001†

Data are median (1st, 3rd) quartile unless otherwise indicated. The statistical tests compare medians across the four cohorts. *Comparison of three cohorts. †Comparison of current smoking prevalence between four cohorts.

The prevalence of renoprotective treatment, predominantly with ACE inhibitors or angiotensin receptor blockers, was very high, ranging from ~95% in FinnDiane to ~75% in the Joslin cohort.

By design, all patients had persistent macroalbuminuria, but the cohorts differed by extent of albuminuria, with lowest rate in FinnDiane (median 321 mg/g) and highest in the Joslin cohort (median 718 mg/g). Baseline albuminuria was below the threshold for macroalbuminuria in some patients, as at least two of three consecutive albumin measurements had to be in the macroalbuminuria range. In the INSERM cohort, ACR was

unavailable so urinary albumin concentration was used for defining albuminuria. Current smoking prevalence was highest in the Steno (44%) and FinnDiane (36%) cohorts and lowest (26%) in the Joslin cohort.

Comparison of Risk of ESRD in Study Cohorts

There were 505 cases of ESRD in 1,518 patients followed for a total of 15,685 patient-years. This accounted for an overall incidence rate of ESRD 32.2 per 1,000 patient-years. The summary of events and follow-up time is shown for each cohort in Table 3. The median follow-up time in

patients who remained alive ranged from 11–12 years in the FinnDiane, Joslin, and INSERM cohorts to ~16 years in the Steno cohort. The follow-up time was much shorter in patients who developed ESRD or died, with medians ranging from 6 to 9 years. Since the cohorts differed significantly by eGFR at baseline, the incidence rates in Table 3 are stratified by CKD stages. The relationship between CKD stage and incidence of ESRD was observed in every cohort. The highest incidence rate of ESRD in CKD stages 1 and 2 was in the Joslin cohort, while the highest incidence of ESRD in CKD stage 3 was in the FinnDiane cohort. With CKD stages combined,

Table 3—Analysis of incidence rates of ESRD and rates of mortality unrelated to ESRD in the four study cohorts

Characteristic	Joslin cohort	FinnDiane cohort	Steno cohort	INSERM cohort
No. of ESRD	159	186	99	61
No. of non-ESRD deaths	40	67	83	38
No. of alive without ESRD	233	233	186	133
Follow-up for ESRD and deaths in years	7.3 (5.0, 10.8)	8.6 (5.1, 11.5)	8.2 (5.5, 11.6)	6.5 (4.1, 12.6)
Follow-up for alive in years	10.7 (7.2, 14.7)	11.6 (7.2, 13.3)	15.8 (13.5, 18.5)	11.9 (7.2, 15.7)
Incidence rate of ESRD (per 1,000 patient-years)				
CKD 1	25.9	13.1	10.1	11.9
CKD 2	46.3	33.3	14.8	24.1
CKD 3	53.7	75.0	53.4	45.2
Rate of mortality unrelated to ESRD (per 1,000 patient-years)				
CKD 1	10.8	13.1	17.1	11.9
CKD 2	7.8	16.6	17.0	16.4
CKD 3	8.1	13.9	23.3	21.0

Follow-up times are presented as median (1st, 3rd quartile).




Figure 1—Comparison of cumulative risk of ESRD and mortality unrelated to ESRD after 10 years of follow-up among the four study cohorts ordered by decreasing risk of ESRD.

the incidence rates of ESRD were 37.2 per 1,000 patient-years in Joslin, 40.5 per 1,000 patient-years in FinnDiane, 22.0 per 1,000 patient-years in Steno, and 26.2 per 1,000 patient-years in INSERM. Cumulative incidence of ESRD among the study cohorts as of the 10th year of follow-up is shown in Fig. 1. It was 31.1% in Joslin, 25.9% in FinnDiane, 17.8% in INSERM, and 16.5% in Steno cohorts.

Comparison of Mortality Unrelated to ESRD

In the four cohorts, 228 deaths unrelated to ESRD occurred, which accounted

for an overall rate of mortality unrelated to ESRD of 14.5 per 1,000 patient-years, two times lower than the incidence rate of ESRD. The majority of these deaths were due to cardiovascular causes. Mortality rates were not related to CKD stage (Table 3) but were different among cohorts. The nonstratified mortality rates were 9.4 per 1,000 patient-years in Joslin, 14.6 per 1,000 patient-years in FinnDiane, 18.5 per 1,000 patient-years in Steno, and 16.3 per 1,000 patient-years in INSERM. The cumulative incidence of deaths unrelated to ESRD is shown in Fig. 1. At 10 years they were 7.1% in

the Joslin cohort, 9.1% in FinnDiane, 13.7% in INSERM, and 15.4% in Steno.

Competing Risk Regression for ESRD and Mortality Unrelated to ESRD

Table 4 presents the results from proportional subhazards models for the risk of ESRD (on the left) and mortality unrelated to ESRD (on the right). Risk factors associated with ESRD were lower baseline eGFR, higher baseline ACR, higher HbA_{1c} and systolic blood pressure, younger age at study entry (or shorter type 1 diabetes duration), and male sex. Risk factors for mortality were older age, smoking, and higher baseline eGFR.

The differences in ESRD risk among the study cohorts remained in the presence of covariates. ESRD risk was highest in the Joslin cohort, hazard ratio (HR) and 95% CI 1.44 (1.14, 1.84), while the risk was lowest in the Steno (HR 0.54, 95% CI 0.42, 0.69) and INSERM (HR 0.67, 95% CI 0.49, 0.92) in comparison with FinnDiane, the largest cohort, as the reference. After adjusting for covariates, no significant differences in mortality unrelated to ESRD were observed between the three European cohorts and the adjusted HRs with FinnDiane as reference were numerically small. For Steno it was 1.01 with 95% CI 0.73, 1.41 and for INSERM HR was 0.93, 95% CI 0.61, 1.42. In contrast, risk of deaths unrelated to ESRD in Joslin remained lower, with HR versus FinnDiane 0.67, 95% CI 0.44, 1.02, $P = 0.063$. In comparison with the three European cohorts, combined HR was 0.68, 95% CI 0.53, 0.87, $P = 0.003$.

Table 4—Proportional subhazards models for the risk of ESRD and for mortality unrelated to ESRD in the four study cohorts (FinnDiane as reference) adjusted for sex, age, baseline eGFR, HbA_{1c}, systolic blood pressure, and smoking status

Covariates	Risk of ESRD		Mortality unrelated to ESRD*	
	HR (95% CI)	<i>P</i> value	HR (95% CI)	<i>P</i> value
Male sex	1.37 (1.13, 1.68)	0.002	1.23 (0.92, 1.63)	0.17
Age (10-year increase)	0.66 (0.59, 0.74)	<0.001	2.12 (1.84, 2.44)	<0.001
Baseline eGFR (10 mL/min increase)	0.73 (0.70, 0.77)	<0.001	1.08 (1.02, 1.14)	0.008
HbA _{1c} (1% increase)	1.22 (1.15, 1.29)	<0.001	1.10 (1.00, 1.21)	0.059
Systolic blood pressure (10 mmHg increase)	1.14 (1.08, 1.20)	<0.001	0.99 (0.92, 1.06)	0.74
Current smoking	1.21 (1.00, 1.47)	0.048	1.78 (1.36, 2.33)	<0.001
Joslin vs. FinnDiane	1.44 (1.14, 1.84)	0.003	0.67 (0.44, 1.02)**	0.063**
Steno vs. FinnDiane	0.54 (0.42, 0.69)	<0.001	1.01 (0.73, 1.41)	0.94
INSERM vs. FinnDiane	0.67 (0.49, 0.92)	0.013	0.93 (0.61, 1.42)	0.74

Adjusting for serum cholesterol and ACR in cohorts with available data had a small impact on the differences in ESRD risk or mortality unrelated to ESRD between cohorts and did not influence statistical inferences. Adjusting for age at type 1 diabetes diagnosis or diabetes duration instead of age did not change the statistical inferences on the differences between the cohorts. *In Joslin, 69% of deaths were due to CVD. In FinnDiane, 55% of deaths were due to CVD. In Steno, 67% of deaths were due to CVD. In INSERM, causes of deaths were not available. **In comparison with three other cohorts HR 0.68, $P = 0.003$.

Table 5—Estimated mean slopes of renal decline expressed in mL/min/1.73 m²/year in the four study cohorts with the crude and covariate-adjusted differences between them

Cohort	Unadjusted mean slope (95% CI)	Differences between cohorts (relative to FinnDiane cohort)			
		Unadjusted		Covariate-adjusted	
		Estimate	P value	Estimate	P value
FinnDiane (reference)	−4.0 (−4.4, −3.6)				
Joslin	−5.2 (−5.7, −4.8)	−1.2 (−1.8, 0.7)	<0.001	−1.0 (−1.6, −0.5)	<0.001
Steno	−3.3 (−3.7, −2.8)	0.7 (0.2, 1.3)	0.012	0.9 (0.3, 1.4)	0.002
INSERM	−4.1 (−4.6, −3.5)	−0.1 (−0.7, 0.6)	0.92	−0.2 (−0.8, 0.5)	0.57

Adjusted for sex, age, HbA_{1c}, systolic blood pressure, antihypertensive treatment, and smoking status. Further adjusting for serum cholesterol and ACR in cohorts with available data did not influence statistical inferences about the differences between the cohorts. Baseline eGFR is not included in the covariate set, as it is already present in joint model specification.

Comparison of Slopes of eGFR Loss Between Cohorts

Unadjusted estimates (with 95% CI) of mean rate of renal function (eGFR) decline in each cohort were −5.2 (−5.7, −4.8) mL/min/1.73 m²/year (Joslin), −4.0 (−4.4, −3.6) mL/min/1.73 m²/year (FinnDiane), −4.1 (−4.6, −3.5) mL/min/1.73 m²/year (INSERM), and −3.3 (−3.7, −2.8) mL/min/1.73 m²/year (Steno). Estimated differences between cohorts from joint longitudinal-survival model, which incorporates informative censoring of the eGFR data in patients with fast renal function decline, are provided in Table 5. After adjusting for covariates (sex, age, HbA_{1c}, systolic blood pressure, antihypertensive treatment, and current smoking), the differences between cohorts remained largely unchanged, with the steepest slopes observed in the Joslin cohort and negligible difference between the FinnDiane and INSERM cohorts, while slopes in the Steno cohort were significantly shallower. The adjusted differences from the reference (FinnDiane) were 1.0 (95% CI 0.5, 1.6) mL/min steeper in Joslin, 0.2 (95% CI −0.5, 0.8) mL/min steeper in INSERM, and 0.9 (95% CI: 0.3, 1.4) mL/min shallower in the Steno cohort. Additional adjustment for ACR and serum cholesterol in a model with the INSERM cohort excluded (as no data were available) did not significantly change estimated differences in slopes.

CONCLUSIONS

In this international follow-up study of four large cohorts of patients with type 1 diabetes with macroalbuminuria, we examined differences among countries in the risk of progression to ESRD and mortality unrelated to ESRD. There are

several major findings of our study. First, despite almost universal treatment with renoprotective drugs, ESRD risk is high and varied dramatically among the study cohorts: the Joslin cohort from New England, U.S., had the highest risk of ESRD, whereas the Steno Copenhagen cohort from Denmark had the lowest, and the other cohorts, FinnDiane and INSERM, had an intermediate ESRD risk. The second finding is related to our long-term follow-up with serial eGFR measurements. We were able to show that international differences in ESRD risk are very well reflected in differences in average slopes of renal decline many years before onset of ESRD. The third finding is that the pattern of ESRD risk was virtually reversed for mortality unrelated to ESRD, which was mainly due to cardiovascular disease (CVD) causes. The mortality was highest in the Steno cohort and lowest in the Joslin cohort. Both institutions are considered the world excellence centers for treatment of type 1 diabetes.

In contrast to recently expressed opinion (13), striking international differences in ESRD risk and mortality unrelated to ESRD could not be explained by so-called “competing risks.” It was postulated that in populations with higher deaths unrelated to ESRD, patients with proteinuria and CKD 3 would die before developing ESRD, while lower mortality could allow more patients to progress from CKD stage 3 to ESRD. In our study, the differences among centers in deaths unrelated to ESRD occurred mainly in patients with CKD stages 1–2 and were unrelated to baseline eGFR and eGFR slopes. Differences in eGFR slopes among cohorts were present many years before ESRD onset. This indicates that the international variation

in risk of ESRD is due to different intensity of disease process that underlies progression of diabetic nephropathy. As a result of that, in the Joslin cohort, there were almost twice as many fast progressors to ESRD as in the Steno cohort (28). On the other hand, Steno had more than two times more frequent deaths unrelated to ESRD in comparison with Joslin.

From our findings, we can consider progression to ESRD and mortality unrelated to ESRD, mainly due to CVD, as independent disease processes. We identified two sets of risk factors for them, and they overlapped only partially. Interestingly, the distributions of risk factors varied between the countries; however, controlling for them in regression models did not materially change the pattern of differences in eGFR decline, in risks of ESRD and in mortality unrelated to ESRD. Therefore, the international differences in both outcomes could be due to unknown genetic or environmental factors that vary among populations, different health attitudes, or alternatively, they might be attributed to gene-environment interactions. The nature of genetic factors is being explored in the recent JDRF DNCRI, which dissects the genetic architecture of diabetic nephropathy in type 1 diabetes. The research on the role of environmental factors determining variation in risk of progression to ESRD and mortality in patients with type 1 diabetes with advanced diabetic nephropathy needs to be developed. It should provide new knowledge that could facilitate the development of new, more effective interventions to reduce risk of these two life-limiting outcomes.

Some recent publications showed variation in risk of ESRD among several

countries (8–13). Whereas those studies aimed to examine lifetime risk of ESRD since the onset of diabetes, our study focused specifically on patients with type 1 diabetes who had advanced diabetic nephropathy at baseline and were subjected to specialized care and treatment for 3–18 years in four different health care systems. Unlike those epidemiological observations, our study provides more specific insight into disease mechanisms that underlie renal decline in patients with advanced nephropathy during follow-up, and it assessed mortality as an additional outcome. Overall combined risk of ESRD and mortality unrelated to ESRD was very high in our cohorts. Optimistic conclusions from the national registry studies should not obscure the opposite prognosis in high-risk patients. These individuals need new, effective, possibly aggressive interventions targeting both kidney and cardiovascular diseases. These two important clinical problems have different determinants, risk factors, and mechanisms but should be addressed simultaneously.

Our study has considerable strengths, such as a very large sample size, prospective design, and long follow-up with serial eGFR determinations. We also have to acknowledge its limitations. The cohorts varied by designs and patient ascertainment procedures, and many biochemical measurements were performed locally in study centers. The INSERM cohort lacked complete data on lipid profile and urinary creatinine. Due to the design of GENESIS and GENEIAB studies, prospective follow-up was unavailable in some of study participants.

The follow-up outcomes in the study were ascertained in a prospective manner. Patients in the Joslin and Steno Copenhagen clinics, most under care early in course of their type 1 diabetes, seem to well represent populations of eastern Massachusetts and the Copenhagen metropolitan area. The FinnDiane cohort has excellent external validity for the whole population of Finland, and INSERM patients are a sample from populations of France and Belgium. Thus, the limitations cannot undermine the main message of our study and its external validity, that the natural history of advanced diabetic nephropathy and burden of mortality in type 1

diabetes is very high and variable among countries.

Funding. This study was supported by the JDRF DNCRI (grant no. 17-2013-8) subproject “Search for genes determining time to onset of ESRD in type 1 diabetes patients with proteinuria” to S.H., P.R., P.-H.G., and A.S.K.; National Institutes of Health grants DK-041526 to A.S.K. and AG-024824 to A.T.G.; and Joslin Diabetes Research Center grant P30 DK036836, the Folkhälsan Research Foundation, the Wilhelm and Else Stockmann Foundation, the Liv och Hälsa Society, Helsinki University Central Hospital Research Funds (EVO), and the Academy of Finland (275614 and 299200) to E.V., N.S., C.F., V.H., and P.-H.G.

Duality of Interest. No potential conflicts of interest relevant to this article were reported.

Author Contributions. J.S. contributed to the study design, performed data analysis, interpreted the results, and drafted the manuscript. A.M.S., E.V., T.S.A., B.G., N.S., S.C., M.L., K.M., C.F., and V.H. collected the research data and were responsible for data management and contributed to data analysis. M.M., A.T.G., D.-A.T., C.Y.W., J.C.M., H.N., M.P., S.S.R., M.G.P., S.H., P.R., and P.-H.G. all contributed to the study design, plans of data analysis, interpretation of the results, and editing of the manuscript. A.S.K. was responsible for the study design, supervised data collection and data analysis, and contributed to drafting and editing of the manuscript. A.S.K. is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Prior Presentation. Parts of this study were presented and published in abstract and oral forms at the 52nd Annual Meeting of the European Association for the Study of Diabetes, Munich, Germany, 13–16 September 2016.

References

- Andersen AR, Christiansen JS, Andersen JK, Kreiner S, Deckert T. Diabetic nephropathy in type 1 (insulin-dependent) diabetes: an epidemiological study. *Diabetologia* 1983;25:496–501
- Krolewski AS, Warram JH, Christlieb AR, Busick EJ, Kahn CR. The changing natural history of nephropathy in type I diabetes. *Am J Med* 1985;78:785–794
- Borch-Johnsen K, Kreiner S. Proteinuria: value as predictor of cardiovascular mortality in insulin dependent diabetes mellitus. *Br Med J (Clin Res Ed)* 1987;294:1651–1654
- Rossing P, Hougaard P, Borch-Johnsen K, Parving HH. Predictors of mortality in insulin dependent diabetes: 10 year observational follow up study. *BMJ* 1996;313:779–784
- Jorsal A, Tarnow L, Flyvbjerg A, Parving HH, Rossing P, Rasmussen LM. Plasma osteoprotegerin levels predict cardiovascular and all-cause mortality and deterioration of kidney function in type 1 diabetic patients with nephropathy. *Diabetologia* 2008;51:2100–2107
- Rosolowsky ET, Skupien J, Smiles AM, et al. Risk for ESRD in type 1 diabetes remains high

despite renoprotection. *J Am Soc Nephrol* 2011;22:545–553

7. Forsblom C, Harjutsalo V, Thorn LM, et al.; FinnDiane Study Group. Competing-risk analysis of ESRD and death among patients with type 1 diabetes and macroalbuminuria. *J Am Soc Nephrol* 2011;22:537–544

8. Möllsten A, Svensson M, Waernbaum I, et al.; Swedish Childhood Diabetes Study Group; Diabetes Incidence Study in Sweden; Swedish Renal Registry. Cumulative risk, age at onset, and sex-specific differences for developing end-stage renal disease in young patients with type 1 diabetes: a nationwide population-based cohort study. *Diabetes* 2010;59:1803–1808

9. Lecaie TJ, Klein BE, Howard KP, Lee KE, Klein R. Risk for end-stage renal disease over 25 years in the population-based WESDR cohort. *Diabetes Care* 2014;37:381–388

10. Gagnum V, Saeed M, Stene LC, Leivestad T, Joner G, Skriverhaug T. Low incidence of end-stage renal disease in childhood-onset type 1 diabetes followed for up to 42 years. *Diabetes Care* 2018;41:420–425

11. Costacou T, Orchard TJ. Cumulative kidney complication risk by 50 years of type 1 diabetes: the effects of sex, age, and calendar year at onset. *Diabetes Care* 2018;41:426–433

12. Helve J, Sund R, Arffman M, et al. Incidence of end-stage renal disease in patients with type 1 diabetes. *Diabetes Care* 2018;41:434–439

13. Bakris GL, Molitch M. Are all patients with type 1 diabetes destined for dialysis if they live long enough? Probably not. *Diabetes Care* 2018;41:389–390

14. Skupien J, Warram JH, Smiles AM, et al. The early decline in renal function in patients with type 1 diabetes and proteinuria predicts the risk of end-stage renal disease. *Kidney Int* 2012;82:589–597

15. Skupien J, Warram JH, Smiles AM, Stanton RC, Krolewski AS. Patterns of estimated glomerular filtration rate decline leading to end-stage renal disease in type 1 diabetes. *Diabetes Care* 2016;39:2262–2269

16. Thorn LM, Forsblom C, Fagerudd J, et al.; FinnDiane Study Group. Metabolic syndrome in type 1 diabetes: association with diabetic nephropathy and glycemic control (the FinnDiane study). *Diabetes Care* 2005;28:2019–2024

17. Groop P-H, Thomas MC, Moran JL, et al.; FinnDiane Study Group. The presence and severity of chronic kidney disease predicts all-cause mortality in type 1 diabetes. *Diabetes* 2009;58:1651–1658

18. Lajer M, Jorsal A, Tarnow L, Parving H-H, Rossing P. Plasma growth differentiation factor-15 independently predicts all-cause and cardiovascular mortality as well as deterioration of kidney function in type 1 diabetic patients with nephropathy. *Diabetes Care* 2010;33:1567–1572

19. Marre M, Jeunemaitre X, Gallois Y, et al. Contribution of genetic polymorphism in the renin-angiotensin system to the development of renal complications in insulin-dependent diabetes: Genetique de la Nephropathie Diabetique (GENEDIAB) study group. *J Clin Invest* 1997;99:1585–1595

20. Hadjadj S, Péan F, Gallois Y, et al.; Genesis France-Belgium Study. Different patterns of insulin resistance in relatives of type 1 diabetic patients with retinopathy or nephropathy: the

Genesis France-Belgium Study. *Diabetes Care* 2004;27:2661–2668

21. Hadjadj S, Cariou B, Fumeron F, et al.; French JDRF Diabetic Nephropathy Collaborative Research Initiative; SURDIAGENE study group; DIABHYCAR study group. Death, end-stage renal disease and renal function decline in patients with diabetic nephropathy in French cohorts of type 1 and type 2 diabetes. *Diabetologia* 2016;59:208–216

22. Krolewski AS, Warram JH, Forsblom C, et al. Serum concentration of cystatin C and risk of end-stage renal disease in diabetes. *Diabetes Care* 2012;35:2311–2316

23. Andrésdóttir G, Jensen ML, Carstensen B, et al. Improved prognosis of diabetic nephropathy in type 1 diabetes. *Kidney Int* 2015;87:417–426

24. Levey AS, Stevens LA, Schmid CH, et al.; CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. *Ann Intern Med* 2009;150:604–612

25. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. *J Am Stat Assoc* 1999;94:496–509

26. Wu MC, Hunsberger S, Zucker D. Testing for differences in changes in the presence of

censoring: parametric and non-parametric methods. *Stat Med* 1994;13:635–646

27. Skupien J, Warram JH, Niewczas MA, et al. Synergism between circulating tumor necrosis factor receptor 2 and HbA_{1c} in determining renal decline during 5–18 years of follow-up in patients with type 1 diabetes and proteinuria. *Diabetes Care* 2014;37:2601–2608

28. Krolewski AS, Skupien J, Rossing P, Warram JH. Fast renal decline to end-stage renal disease: an unrecognized feature of nephropathy in diabetes. *Kidney Int* 2017;91:1300–1311